← ANALYST RATINGS · TIPRANKS
Ascentage Pharma Group International Unsponsored ADR (AAPG): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $43.40, the highest $48.00, the lowest $33.00. The average is +182.4% from the last price of $15.37.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $46.00 | Buy | +199.3% | Initiated | 14.10.26on TipRanks Oct 15 03:30 | −0.3%next day −1.4% | ↗ |
| Silvan Turkcan★★★★★★★★★★#10721 · hits 17% · avg −13.5% | Citizens JMP | $35.00 | Buy | +127.7% | Initiated | 13.10.26on TipRanks Oct 14 01:55 | −1.6%next day −0.3% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $46.00 → $33.00−28.3% | Buy | +114.7% | Reiterated | 08.10.26on TipRanks Oct 9 02:40 | −2.2%next day +0.8% · 5 days +1.2% | ↗ |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $15.00 → $16.50+10.0% | Hold | +7.4% | Reiterated | 07.10.26on TipRanks 13:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $15.00 → $16.50+10.0% | Hold | +7.4% | Reiterated | 07.10.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $14.50 → $16.00+10.3% | Hold | +4.1% | Reiterated | 07.10.26on TipRanks 12:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $14.50 → $16.00+10.3% | Hold | +4.1% | Reiterated | 07.10.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $15.00 → $16.00+6.7% | Hold | +4.1% | Reiterated | 07.10.26on TipRanks 12:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $15.00 → $16.00+6.7% | Hold | +4.1% | Reiterated | 07.10.26on TipRanks 12:05 | — | |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $45.00 | Buy | +192.8% | Reiterated | 02.09.26on TipRanks 09:10 | +3.1%next day +2.2% · 5 days +0.1% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | — | Buy | — | Reiterated | 21.08.26on TipRanks 07:55 | −2.3%next day −1.4% · 5 days +7.0% | ↗ |
| Jeff Jones★★★★★★★★★★#749 · hits 46% · avg +20.3% | Oppenheimer | $45.00 | Buy | +192.8% | Reiterated | 21.08.26on TipRanks 07:50 | −2.3%next day −1.4% · 5 days +7.0% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $48.00 | Buy | +212.3% | Reiterated | 20.08.26on TipRanks Aug 21 10:06 | −3.1%next day −2.3% · 5 days +7.0% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $48.00 | Buy | +212.3% | Reiterated | 01.06.26on TipRanks 09:25 | −4.9%next day −3.4% · 5 days −7.7% | ↗ |
| James Shin★★★★★★★★★★#4468 · hits 57% · avg +7.3% | Deutsche Bank | $40.00 | Buy | +160.2% | Initiated | 24.04.26on TipRanks 05:30 | +6.4%next day −2.6% · 5 days −3.5% | ↗ |
| Unknown Analyst | Rodman & Renshaw | $48.00 | Buy | +212.3% | Initiated | 13.01.26on TipRanks Jan 14 10:05 | −1.9%next day +2.5% · 5 days −3.8% | ↗ |
| Christopher Liu★★★★★★★★★★#2941 · hits 44% · avg +8.9% | Lucid Capital | $50.00 | Buy | +225.3% | Initiated | 15.12.25on TipRanks 18:25 | +6.9%next day −2.1% · 5 days −6.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Ascentage Pharma Group International Unsponsored ADR
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 09.10.26: target $42.75 at a price of $14.55 (+193.8%); now: $42.00 at $15.37 (+173.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 3 | 4 | 3 | 5 |
| Buy | 0 | 0 | 0 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 31.03.27 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.30 (from $-0.35 to $-0.26). Last quarter: $-0.32.
Sales
Next quarter’s sales estimate — $50M (from $47M to $53M). Last quarter: $44M.
Best top-analyst consensus in the sector · General
About Ascentage Pharma Group International Unsponsored ADR
- CEO: Dajun Yang
- Employees: 767
- Suzhou Industrial Park, Suzhou, JS, 215000, CN
- www.ascentage.com
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.
Data from the stock’s TipRanks forecast page, read 52 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗